Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC | MicrobiomeTrials← Back to trialsNCT07733830
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-31Est. Completion: 2027-12-31
Enrollment target: 120 participants Locations- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- Henan Cancer Hospital, Zhengzhou, Hanan, China
- Liaoning Cancer Hospital, Shenyang, Liaoning, China
- Shanxi Cancer Hospital, Taiyuan, Shanxi, China
- Sichuan Cancer Hospital, Chengdu, Sichuan, China
- Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China
Other microbiome trials you might be interested in
Esophageal CancerGastric (Cardia, Body) Cancer
The overall goal of this project is to understand the role of genetics in the etiology and prevention of upper gastroint…
Taiyuan, ChinaCompleted Mar 18, 2020
Advanced Esophageal Squamous Cell CarcinomaMetastatic Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administ…
Multiple LocationsEst. completion Feb 28, 2028
Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Esophageal AdenocarcinomaMetastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Esophageal AdenocarcinomaUnresectable Gastric AdenocarcinomaUnresectable Gastroesophageal Junction Adenocarcinoma
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to pacli…
Little Rock, United StatesEst. completion Oct 31, 2027